Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Supercharged immune cells take on tough lymphoma

NCT ID NCT03196830

Disease control Sponsor: The First Affiliated Hospital of Soochow University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 2 trial tested a special type of immune cell therapy called CAR-T in 168 patients with relapsed or refractory non-Hodgkin lymphoma. The CAR-T cells were designed to recognize four different targets on cancer cells (CD19, CD20, CD22, and CD30). Patients received the cells after a short course of chemotherapy and were followed for at least two years to see how well the treatment worked and what side effects occurred.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CAR-T cells targeting CD19, CD20, CD22, and CD30
What this could lead to
If successful, this could offer a new treatment option for patients with hard-to-treat non-Hodgkin lymphoma who have run out of standard therapies.
What could go wrong
This is a single-arm, early-phase trial without a comparison group, so results may not be definitive. CAR-T therapy can cause serious side effects like cytokine release syndrome and neurological problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

168 people

The number who actually took part.

Started

Jun 2017

Finished

Jan 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histological detection confirmed CD19/CD20/CD22/CD30 postive non-Hodgkin lymphoma * Recieved more than 2 lines of chemotherapy * With contraindications of hematopoietic stem cell transplantation or relapse after hematopoietic stem cell transplantation * Expected survival more than 3 months * Karmofsky performance score ≤ 60, and ECOG ≥ 2. * Enough organ function: EF≥50%; normal ECG; CCR≥40ml/min; ALT and AST ≤ 3 × upper limitation of normal, T-BIL ≤ 2.0mg/dl; PT and APTT \< 2 × upper limitation of normal; SpO2 \> 92% * CBC results: Hb ≥ 80g/L, ANC \> 1 × 10E9/L, Plt ≥ 50 × 10E9/L * Results of pregnant test should be negative, and agree to conception control during treatment and 1 year after CAR-T infusion * With measurable disease * Written informed consent could be acquired Exclusion Criteria: * Received immunol suppression treatment or steroids in recent 1 week before recruitment * Uncontrolled infection * HIV positive patients * Active HBV or HCV infection * Women in pregnancy and lactation * Refuse to conception control during treatment and 1 year after CAR-T infusion * Uncured malignancies other than non-Hodgkin lymphoma * Have participated similar trial for treating relapse/refractory non-Hodgkin lymphoma * Inheritated immune deficiancy * Severe heart disease

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Car - T CD19/CD20/CD22/CD30 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-Hodgkin lymphoma Recurrence refractory malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Car - T CD19/CD20/CD22/CD30 Refractory non-Hodgkin lymphoma Relapsed non-Hodgkin lymphoma

Contacts and locations

Locations

  • the First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, 215006, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.